Separately, ValuEngine upgraded shares of Atrion from a “hold” rating to a “buy” rating in a report on Monday, February 4th.
Shares of NASDAQ ATRI traded up $6.47 during midday trading on Wednesday, hitting $869.97. The company had a trading volume of 4,201 shares, compared to its average volume of 6,550. Atrion has a twelve month low of $560.65 and a twelve month high of $948.03. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of 47.31 and a beta of 0.44.
Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Featured Article: What is an investor looking for in an SEC filing?
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.